Prevymis

Chemical Nameletermovir
Dosage FormTablet (oral; 240 mg, 480 mg); injectable (intravenous; 20 mg/mL)
Drug ClassAntivirals
SystemRespiratory, Cardiovascular, Ocular, Nervous
CompanyMerck & Co.
Approval Year2017

Indication

  • Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Prevymis (letermovir) Prescribing Information2020Merck